Title: Adaptive Randomization of Neratinib in Early Breast Cancer.
Journal: The New England journal of medicine20160707
Title: A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20131101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters20130801
Title: Dual blockade of HER2 - twice as good or twice as toxic?
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))20121101
Title: New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
Journal: Cancer treatment reviews20120801
Title: Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Journal: Biochemical pharmacology20120801
Title: Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Journal: International journal of cancer20120701
Title: A double-blind, randomized, multiple-dose, parallel-group study to characterize the occurrence of diarrhea following two different dosing regimens of neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor.
Journal: Cancer chemotherapy and pharmacology20120701
Title: Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo.
Journal: Molecular pharmacology20120701
Title: Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy.
Journal: International journal of oncology20120601
Title: Neratinib (HKI-272) in the treatment of breast cancer.
Journal: Future oncology (London, England)20120601
Title: Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study.
Journal: Japanese journal of clinical oncology20120401
Title: A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
Journal: Molecular bioSystems20120401
Title: Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation.
Journal: Drug development and industrial pharmacy20120301
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology20111030
Title: Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Journal: Breast (Edinburgh, Scotland)20111001
Title: A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
Journal: Molecular bioSystems20110601
Title: The search for improved systemic therapy of non-small cell lung cancer--what are today's options?
Journal: Lung cancer (Amsterdam, Netherlands)20110601
Title: Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects.
Journal: British journal of clinical pharmacology20110401
Title: Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors.
Journal: Journal of medicinal chemistry20110310
Title: [Novel target therapies used in breast cancer management].
Journal: Voprosy onkologii20110101
Title: Irreversible EGFR inhibitor EKB-569 targets low-LET γ-radiation-triggered rel orchestration and potentiates cell death in squamous cell carcinoma.
Journal: PloS one20110101
Title: Reversible covalent binding of neratinib to human serum albumin in vitro.
Journal: Drug metabolism letters20101201
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology20101124
Title: A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20100801
Title: Characterization of HKI-272 covalent binding to human serum albumin.
Journal: Drug metabolism and disposition: the biological fate of chemicals20100701
Title: Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20100620
Title: The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.
Journal: Cancer investigation20100501
Title: Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology20100310
Title: [Management of metastatic HER2-positive breast cancer: present and future].
Journal: Bulletin du cancer20100301
Title: Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions.
Journal: Cancer treatment reviews20091201
Title: [New development in the treatment of breast cancer. II. Future anti-HER2 therapy].
Journal: Gan to kagaku ryoho. Cancer & chemotherapy20091201
Title: Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Journal: Expert opinion on investigational drugs20091101
Title: A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20090401
Title: Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.
Journal: Bioorganic & medicinal chemistry letters20090101
Title: The development of HKI-272 and related compounds for the treatment of cancer.
Journal: Archiv der Pharmazie20080801
Title: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer20080601
Title: The T790M 'gatekeeper' mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Journal: Molecular cancer therapeutics20080401
Title: Enzyme replacement therapy for Gaucher's disease in patient treated for non-small cell lung cancer.
Journal: Anticancer research20080101
Title: HKI-272 in non small cell lung cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research20070801
Title: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Journal: Oncogene20070726
Title: Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.
Journal: Cancer cell20070701
Title: Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Journal: Bioorganic & medicinal chemistry20070601
Title: Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
Journal: Cancer biology & therapy20070501
Title: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Journal: The oncologist20070301
Title: Pharmacology of epidermal growth factor inhibitors.
Journal: The International journal of biological markers20070101
Title: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Journal: Cancer research20060701
Title: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Journal: Cancer cell20060601
Title: EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Journal: Cancer cell20060601
Title: Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Journal: Journal of medicinal chemistry20050224
Title: Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Journal: Cancer research20040601
